Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Endocrinol Metab. 2014 May;99(5):E855-61. doi: 10.1210/jc.2013-4171. Epub 2014 Feb 25.

Soluble α-klotho and its relation to kidney function and fibroblast growth factor-23.

Author information

1
Clinical Research Unit (A.S., M.T.), Department of Nephrology, and Centre for Individualized Medicine in Arterial Diseases (L.P., L.M.R.), Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, 5000 Odense C, Denmark; Institute of Clinical Research (A.S., M.T.) and Institute of Molecular Medicine (Y.L., S.X., M.T.), Cardiovascular and Renal Research, University of Southern Denmark, 5000 Odense C, Denmark; Labor Dr Limbach und Kollegen (H.J.R.), Medizinisches Versorgungszentrum, 69126 Heidelberg, Germany; and Institute of Nutritional Science (B.H.), University of Potsdam, 14558 Nuthetal/Potsdam, Germany.

Abstract

CONTEXT:

Relations between fibroblast growth factor-23 (FGF-23), soluble α-klotho (s-α-klotho), and kidney function in chronic kidney disease (CKD) are still unclear. Especially the role of s-α-klotho requires further study.

OBJECTIVES:

Our objectives were to analyze the relation of s-α-klotho to estimated glomerular filtration rate (eGFR), FGF-23, and other parameters of calcium-phosphate metabolism and to investigate the response of s-α-klotho to cholecalciferol.

PATIENTS, DESIGN, AND SETTING:

Twenty-four CKD (stage 1-5) patients participated in this 8-week randomized controlled trial (vitamin D and chronic renal insufficiency).

INTERVENTIONS:

Interventions included 40 000 IU cholecalciferol or placebo weekly.

MAIN OUTCOME MEASURE:

S-α-klotho was determined by ELISA with antihuman klotho antibodies 67G3 and 91F1.

RESULTS:

For all patients, s-α-klotho concentrations did not differ between CKD stages. When patients were subdivided based on FGF-23 concentrations, a positive association of s-α-klotho with eGFR became apparent in patients with lower than median FGF-23 concentrations but not in those above median value. Patients with s-α-klotho below 204 pg/mL showed higher age, lower phosphate clearance, and lower bone-specific alkaline phosphatase compared with patients with higher s-α-klotho. Treatment with cholecalciferol significantly increased 1,25-dihydroxyvitamin D. The increase of FGF-23 had only borderline significance. There was no significant effect of high-dose cholecalciferol administration for 8 weeks on plasma s-α-klotho.

CONCLUSIONS:

CKD patients with s-α-klotho below 204 pg/mL had higher age, lower phosphate clearance, and lower bone-specific alkaline phosphatase. An association of s-α-klotho with eGFR was observed only in the presence of close to normal, but not high, FGF-23 concentrations. Cholecalciferol treatment did not change s-α-klotho concentrations.

PMID:
24606097
DOI:
10.1210/jc.2013-4171
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center